CD57 ratio as a convenient and useful immunological and prognostic parameter for stage IV carcinoma

  • Authors:
    • Junji Akagi
    • Hideo Baba
  • View Affiliations

  • Published online on: April 10, 2018     https://doi.org/10.3892/ol.2018.8451
  • Pages: 9257-9263
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cluster of differentiation (CD)8+CD57+ T cells are derived through the CD8+ T cell‑differentiation signaling pathway from early differentiated CD27+CD8+CD57‑T cells (early‑CD8+ T cells) to terminal‑differentiated CD27‑CD8+CD57+ T cells (terminal‑CD8+ T cells) via intermediate‑differentiated CD27+CD8+CD57+ T cells (intermediate‑CD8+ T cells). The increase of CD8+CD57+ T cells in the peripheral blood of patients with cancer has been associated with prognosis, which suggests their suitability as a candidate immunological marker. The present study investigated the association of these CD57‑related CD8+ T cell populations in the peripheral blood of 100 Stage IV cancer patients with progression‑free survival (PFS), using a Cox regression model. Univariate analysis indicated that early‑ and intermediate‑CD8+ T cells were associated with shorter PFS, whereas terminal‑CD8+ T cells were associated with longer PFS. A strong inverse correlation was observed between early‑ and terminal‑CD8+ T cells, and multivariate analysis demonstrated that the CD57 ratio (terminal‑CD8+ T cells/early‑CD8+ T cells) was a more significant independent prognostic factor compared with early‑ or terminal‑CD8+ T cells. Patients with a higher CD57 ratio had a significantly longer PFS compared with those with a lower CD57 ratio, in whom terminal‑CD8+ T cells were supposed to be predominant. Conversely, results indicated inhibition of the CD8+ T cell differentiation signaling pathway in patients with a low CD57 ratio, which lead to a predominance of early‑CD8+ T cells, a characteristic of immunosuppressive cells. The present findings suggested that the CD57 ratio appears to be a powerful immunological prognostic parameter obtained from the peripheral blood, precisely reflecting the state of CD8+ T cell‑differentiation.
View Figures
View References

Related Articles

Journal Cover

June-2018
Volume 15 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Akagi J and Akagi J: CD57 ratio as a convenient and useful immunological and prognostic parameter for stage IV carcinoma. Oncol Lett 15: 9257-9263, 2018
APA
Akagi, J., & Akagi, J. (2018). CD57 ratio as a convenient and useful immunological and prognostic parameter for stage IV carcinoma. Oncology Letters, 15, 9257-9263. https://doi.org/10.3892/ol.2018.8451
MLA
Akagi, J., Baba, H."CD57 ratio as a convenient and useful immunological and prognostic parameter for stage IV carcinoma". Oncology Letters 15.6 (2018): 9257-9263.
Chicago
Akagi, J., Baba, H."CD57 ratio as a convenient and useful immunological and prognostic parameter for stage IV carcinoma". Oncology Letters 15, no. 6 (2018): 9257-9263. https://doi.org/10.3892/ol.2018.8451